Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents

@article{Fong2007AntiobesityEO,
  title={Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-\{[5-(trifluoromethyl)pyridin-2-yl]oxy\}propanamide (MK-0364), in Rodents},
  author={T. Fong and Xiao-ming Guan and D. Marsh and Chun-Pyn Shen and D. Stribling and Kim Rosko and Julie Lao and H. Yu and Y. Feng and J. Xiao and Lex H T van der Ploeg and M. Goulet and Williams K. Hagmann and Linus S. Lin and T. Lanza and James P. Jewell and P. Liu and S. Shah and Hongbo Qi and X. Tong and J. Wang and S. Xu and B. Francis and A. Strack and D. Macintyre and L. Shearman},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2007},
  volume={321},
  pages={1013 - 1022}
}
  • T. Fong, Xiao-ming Guan, +23 authors L. Shearman
  • Published 2007
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
    • The cannabinoid-1 receptor (CB1R) has been implicated in the control of energy balance. To explore the pharmacological utility of CB1R inhibition for the treatment of obesity, we evaluated the efficacy of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364) and determined the relationship between efficacy and brain CB1R occupancy in rodents. MK-0364 was shown to be a highly potent CB1R inverse agonist that… CONTINUE READING
    View on ASPET
    ncbi.nlm.nih.gov
    95 Citations
    Highly Influential Citations
    6
    Background Citations
    25
    Methods Citations
    3
    Results Citations
    2
    95 Citations
    Citation Type

    Citation Type

    Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    • 13
    Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans
    • B. Karanam, C. Addy, +14 authors S. Kumar
    • Chemistry, Medicine
    • Xenobiotica; the fate of foreign compounds in biological systems
    • 2010
    • 1
    • Highly Influenced
    In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys
    • 5
    Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist
    • 11
    Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
    • 41
    Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    • 3
    Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
    • 34
    • PDF
    Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    • 14
    Localisation of melanin-concentrating hormone receptor 1 in rat brain and evidence that sleep parameters are not altered despite high central receptor occupancy.
    • 8
    Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
    • 4
    • PDF

    References

    SHOWING 1-10 OF 46 REFERENCES
    Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    • 37
    Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    • 91
    Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
    • 147
    Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
    • 967
    • PDF
    The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats
    • 49
    Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
    • 193
    Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding
    • 139
    Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
    • 1,238
    • PDF
    Observational analysis of feeding induced by Δ9-THC and anandamide
    • 184
    Observational analysis of feeding induced by Delta9-THC and anandamide.
    • 103